Salud,deporte y vulnerabilidad socioeconómica en una comunidad urbana

ObjectiveTo analyse the association between perceived and diagnosed health, sport practice, and the belonging to a vulnerable socioeconomic group.DesignObservational study. Questionnaire.SettingCasablanca neighbourhood. Primary Health Care Area in the city of Zaragoza (Spain).Participants1032 residents aged over 15 years.Main measurementsa) Perceived health using the Health Perception Questionnaire of Davis and Ware; b) diagnosed morbidity; c) sport practice using the Healthy Lifestyles questionnaire-94 of Herrero, Musitu and Gracia, and d) socioeconomic vulnerability based on the occupational, educational and economic conditions of the family unit.ResultsSocioeconomic vulnerability had a statistically significant association with diagnosed health, self-perceived health, and sport practice. Vulnerability and exercise showed a higher influence over self-perceived health than over diagnosed health. In the analysis stratified by gender, the association could only be observed in men.ConclusionsThe impact of health social factors is modulated by gender. Social stratification and lifestyles, such as sport practice, are predictors of self-perceived health and, thus, of the relationship between the population and the use of health services.     

A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants

The lack of an effective licensed vaccine remains one of the most significant gaps in the portfolio of tools being developed to eliminate Plasmodium falciparum malaria. Vaccines targeting erythrocyte invasion – an essential step for both parasite development and malaria pathogenesis – have faced the particular challenge of genetic diversity. Immunity-driven balancing selection pressure on parasite invasion proteins often results in the presence of multiple, antigenically distinct, variants within a population, leading to variant-specific immune responses. Such variation makes it difficult to design a vaccine that covers the full range of diversity, and could potentially facilitate the evolution of vaccine-resistant parasite strains. In this study, we investigate the effect of genetic diversity on invasion inhibition by antibodies to a high priority P. falciparum invasion candidate antigen, P. falciparum Reticulocyte Binding Protein Homologue 5 (PfRH5). Previous work has shown that virally delivered PfRH5 can induce antibodies that protect against a wide range of genetic variants. Here, we show that a full-length recombinant PfRH5 protein expressed in mammalian cells is biochemically active, as judged by saturable binding to its receptor, basigin, and is able to induce antibodies that strongly inhibit P. falciparum growth and invasion. Whole genome sequencing of 290 clinical P. falciparum isolates from across the world identifies only five non-synonymous PfRH5 SNPs that are present at frequencies of 10% or more in at least one geographical region. Antibodies raised against the 3D7 variant of PfRH5 were able to inhibit nine different P. falciparum strains, which between them included all of the five most common PfRH5 SNPs in this dataset, with no evidence for strain-specific immunity. We conclude that protein-based PfRH5 vaccines are an urgent priority for human efficacy trials.     

Clinical Trials with a New Atypical Antipsychotic (Aripiprazole): Gender Specific Information Analysis

ABSTRACT

Introduction: In 1993, the Food and Drug Administration (FDA) published a guideline for the study and evaluation of gender-related differences in clinical trials. However, the extent of the implementation of these recommendations has not been systematically reviewed.

Objectives: To determine the proportion of women in clinical trials of Aripiprazole, a new atypical antipsychotic, and to analyze the resulting information on a gender-specific basis.

Method: A systematic review was conducted in Medline to identify randomized trials that compared this new antipsychotic drug with placebo or with typical or atypical antipsychotics in patients diagnosed with schizophrenia. The FDA Guideline was followed for the study and evaluation of gender-specific results of clinical trials.

Results: Despite the inclusion of female participants in the samples studied, the failure to conduct analyses stratified by sex prevented us from ascertaining the possible differences between men and women in the therapeutic response or in the adverse side effects of treatment with Aripiprazole.